Healthcare provider profile · identity verified

Leslie A Blake, MD

Internal Medicine · NEW ORLEANS, LA · NPI 1639137698

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	766	217
Amlodipine Besylate	Amlodipine Besylate	571	166
Levothyroxine Sodium	Levothyroxine Sodium	519	131
Losartan Potassium	Losartan Potassium	431	126
Rosuvastatin Calcium	Rosuvastatin Calcium	414	131
Hydrochlorothiazide	Hydrochlorothiazide	267	80
Alendronate Sodium	Alendronate Sodium	185	51
Omeprazole	Omeprazole	184	55
Olmesartan Medoxomil	Olmesartan Medoxomil	181	52
Metformin Hcl	Metformin Hcl	162	54
Potassium Chloride	Potassium Chloride	148	47
Pantoprazole Sodium	Pantoprazole Sodium	147	44
Metoprolol Succinate	Metoprolol Succinate	143	44
Gabapentin	Gabapentin	142	41
Alprazolam	Alprazolam	123	41
Ezetimibe	Ezetimibe	119	32
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	113	34
Lorazepam	Lorazepam	102	20
Valsartan	Valsartan	102	30
Escitalopram Oxalate	Escitalopram Oxalate	93	28
Eliquis	Apixaban	87	19
Carvedilol	Carvedilol	82	24
Furosemide	Furosemide	77	24
Ozempic	Semaglutide	77	14
Allopurinol	Allopurinol	75	22
Citalopram Hbr	Citalopram Hydrobromide	74	19
Sertraline Hcl	Sertraline Hcl	74	20
Trazodone Hcl	Trazodone Hcl	73	21
Albuterol Sulfate Hfa	Albuterol Sulfate	72	34
Hydroxyzine Hcl	Hydroxyzine Hcl	72	24
Esomeprazole Magnesium	Esomeprazole Magnesium	70	21
Pravastatin Sodium	Pravastatin Sodium	69	23
Atenolol	Atenolol	64	20
Irbesartan	Irbesartan	64	19
Zolpidem Tartrate	Zolpidem Tartrate	62	18
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	61	11
Fluticasone Propionate	Fluticasone Propionate	59	26
Metformin Hcl Er	Metformin Hcl	57	19
Donepezil Hcl	Donepezil Hcl	53	suppressed
Spironolactone	Spironolactone	53	16
Bupropion Hcl	Bupropion Hcl	49	14
Mirtazapine	Mirtazapine	48	suppressed
Meloxicam	Meloxicam	47	20
Famotidine	Famotidine	45	16
Montelukast Sodium	Montelukast Sodium	44	14
Bupropion Xl	Bupropion Hcl	43	12
Estradiol	Estradiol	42	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	36
Synthroid	Levothyroxine Sodium	41	suppressed
Trulicity	Dulaglutide	41	suppressed
Buspirone Hcl	Buspirone Hcl	40	suppressed
Nifedipine Er	Nifedipine	39	13
Candesartan Cilexetil	Candesartan Cilexetil	38	14
Mounjaro	Tirzepatide	38	suppressed
Chlorthalidone	Chlorthalidone	37	14
Clopidogrel	Clopidogrel Bisulfate	35	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	34	13
Duloxetine Hcl	Duloxetine Hcl	33	suppressed
Lisinopril	Lisinopril	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	13
Jardiance	Empagliflozin	31	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	30	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	29	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	29	suppressed
Valacyclovir	Valacyclovir Hcl	28	suppressed
Verapamil Er	Verapamil Hcl	27	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	26	suppressed
Ibandronate Sodium	Ibandronate Sodium	25	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	25	suppressed
Glimepiride	Glimepiride	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Ciclopirox	Ciclopirox	19	suppressed
Memantine Hcl	Memantine Hcl	19	suppressed
Lovastatin	Lovastatin	18	suppressed
Simvastatin	Simvastatin	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	11
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	17	17
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Prednisone	Prednisone	15	suppressed
Repatha Sureclick	Evolocumab	15	suppressed
Verapamil Hcl	Verapamil Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	13
Diazepam	Diazepam	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Finasteride	Finasteride	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error